Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 1/2001

01.12.2001 | Review Article

Current Management of Fungal Infections

verfasst von: Jacques F. G. M. Meis, Paul E. Verweij

Erschienen in: Drugs | Sonderheft 1/2001

Einloggen, um Zugang zu erhalten

Abstract

The management of superficial fungal infections differs significantly from the management of systemic fungal infections. Most superficial infections are treated with topical antifungal agents, the choice of agent being determined by the site and extent of the infection and by the causative organism, which is usually readily identifiable. One exception is onychomycosis, which usually requires treatment with systemically available antifungals; the accumulation of terbinafine and itraconazole in keratinous tissues makes them ideal agents for the treatment of onychomycosis. Oral candidiasis in immunocompromised patients also requires systemic treatment; oral fluconazole and itraconazole oral solution are highly effective in this setting.
Systemic fungal infections are difficult to diagnose and are usually managed with prophylaxis or empirical therapy. Fluconazole and itraconazole are widely used in chemoprophylaxis because of their favourable oral bioavailability and safety profiles. In empirical therapy, lipid-associated formulations of amphotericin-B and intravenous itraconazole are safer than, and at least as effective as, conventional amphotericin-B (the former gold standard). The high acquisition costs of the lipid-associated formulations of amphotericin-B have limited their use.
Literatur
1.
2.
Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801–8PubMedCrossRef
3.
Tumbarello M, Tacconelli E, Pagano L, et al. Comparative analysis of prognostic indicators of aspergillosis in haematological malignancies and HIV infection. J Infect 1997; 34: 55–60PubMedCrossRef
4.
Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23–32PubMedCrossRef
5.
Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta 1986; 864: 257–304PubMedCrossRef
6.
Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308–29PubMedCrossRef
7.
Schafer-Korting M, Blechschmidt J, Korting HC. Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Mycoses 1996; 39: 329–39PubMedCrossRef
8.
9.
Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259–84PubMedCrossRef
10.
Harari S, Schiraldi G, de Juli E, et al. Relapsing Aspergillus bronchitis in a double lung transplant patient, successfully treated with a new oral antimycotic agent [letter]. Chest 1997; 111: 835–6PubMedCrossRef
11.
Vanden Bossche H. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. In: McGinnis MR, ed. Current topics in medical mycology. New York: Springer-Verlag, 1985: 313–51CrossRef
12.
Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1993; 330: 263–72
13.
Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32 Suppl. 1: 67–87PubMed
14.
Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic infections. Drugs 2001; 61 Suppl. 1: 39–47PubMedCrossRef
15.
16.
Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother 1992; 36: 477–80PubMedCrossRef
17.
Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 83–9
18.
Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991; 324: 580–4
19.
Wildfeuer A, Faergemann J, Laufen H, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994; 37: 127–30PubMedCrossRef
20.
Savin RC, Drake L, Babel D, et al. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. J Am Acad Dermatol 1998; 38: S110–6PubMedCrossRef
21.
Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15: 1003–18PubMedCrossRef
22.
Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs 1996; 52: 209–24PubMedCrossRef
23.
Evans EG. Tinea pedis: clinical experience and efficacy of short treatment. Dermatology 1997; 194 Suppl. 1: 3–6PubMedCrossRef
24.
Noble SL, Forbes RC, Stamm PL. Diagnosis and management of common tinea infections. Am Fam Physician 1998; 58: 163–74PubMed
25.
Farag A, Taha M, Halim S. One-week therapy with oral terbinafine in cases of tinea cruris/corporis. Br J Dermatol 1994; 131: 684–6PubMedCrossRef
26.
Parent D, Decroix J, Heenen M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. Dermatology 1994; 189: 378–81PubMedCrossRef
27.
Gupta AK, De Doncker P, Heremans A, et al. Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. J Am Acad Dermatol 1997; 36: 789–92PubMedCrossRef
28.
Boonk W, de Geer D, de Kreek E, et al. Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules. Mycoses 1998; 41: 509–14PubMedCrossRef
29.
Hickman JG. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. J Am Acad Dermatol 1996; 34: 785–7PubMedCrossRef
30.
Tausch I, Decroix J, Gwiezdzinski Z, et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatol 1998; 37: 140–2PubMedCrossRef
31.
Jahangir M, Hussain I, Ul Hasan M, et al. A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatol 1998; 139: 672–4PubMedCrossRef
32.
Elewski B, Hay RJ. International summit on cutaneous antifungal therapy. 1994 Nov 11–13; Boston, Massachusetts, USA. J Am Acad Dermatol 1995; 33: 816–22PubMedCrossRef
33.
Goodfield MJD. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 1992; 126 Suppl. 39: 33–5PubMedCrossRef
34.
van der Schroeff JG, Cirkel PK, Crijns MB, et al. Arandomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126 Suppl. 39: 36–9PubMedCrossRef
35.
Gupta AK, Scher RK, De Doncker P. Current management of onychomycosis: an overview. Dermatol Clin 1997; 15: 121–35PubMedCrossRef
36.
Willemsen M, De Doncker P, Willems J, et al. Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis. J Am Acad Dermatol 1992; 26: 731–5
37.
Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails: a US analysis. Pharmacoeconomics 1998; 13: 243–56PubMedCrossRef
38.
Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595–600PubMedCrossRef
39.
Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ 1999; 318: 1031–5
40.
Degreef H, Del Palacio A, Mygind S, et al. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Derm Venereol 1999; 79: 221–3PubMedCrossRef
41.
Hay RJ, Clayton YM, Moore MK, et al. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119: 359–66PubMedCrossRef
42.
Kim J-A, Ahn K-J, Kim J-M, et al. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: a 6-week pilot study. Curr Ther Res 1995; 56: 1066–75CrossRef
43.
Li WD, Ping WA, Yu LR, et al. Therapeutic efficacy of intermittent pulse therapy with itraconazole in onychomycosis: a Chinese multicenter trial. 54th Annual Meeting of the American Academy of Dermatology; 1996Feb 10–25; Washington, DC, 1996
44.
Smith DE, Midgley J, Allan M, et al. Itraconazole versus ketoconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV. AIDS 1991; 5: 1367–71PubMedCrossRef
45.
Hay RJ. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis 1990; 12 Suppl. 3: S334–S7PubMedCrossRef
46.
Baily GG, Perry FM, Denning DW, et al. Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994; 8: 787–92PubMedCrossRef
47.
Ruhnke M, Eigler A, Tennagen I, et al. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994; 32: 2092–8PubMed
48.
Willocks L, Leen CLS, Brettle RP, et al. Fluconazole resistance in AIDS patients [letter]. J Antimicrob Chemother 1991; 28: 937–9PubMedCrossRef
49.
Smith D, Midgley J, Gazzard B. A randomised, double-blind study of itraconazole versus placebo in the treatment and prevention of oral or oesophageal candidosis in patients with HIV infection. Int J Clin Prac 1999; 53: 349–52
50.
Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 1997; 50: 477–80PubMedCrossRef
51.
Prentice AG, Warnock DW. Itraconazole more bioavailable in solution [letter]. Blood 1996; 88: 3662–3PubMed
52.
Graybill JR, Vazquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998; 104: 33–9PubMedCrossRef
53.
Cartledge JD, Midgley J, Youle M, et al. Itraconazole cyclo-dextrin solution-effective treatment for HIV-related candidosis unresponsive to other azole therapy [letter]. J Antimicrob Chemother 1994; 33: 1071–3PubMedCrossRef
54.
Phillips P, Zemcov J, Mahmood W, et al. Itraconazole cyclo-dextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 1996; 10: 1369–76PubMedCrossRef
55.
Saag MS, Fessel WJ, Kauffman CA, et al. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses 1999; 15: 1413–7PubMedCrossRef
56.
Lortholary O, Denning DW, Dupont B. Endemic mycoses: a treatment update. J Antimicrob Chemother 1999; 43: 321–31PubMedCrossRef
57.
Kauffman CA. Newer developments in therapy for endemic mycoses. Clin Infect Dis 1994; 19 Suppl. 1: S28–S32PubMedCrossRef
58.
Dismukes WE, Bradsher Jr RW, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992; 93: 489–97PubMedCrossRef
59.
Robinson PA, Knirsch AK, Joseph JA. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis 1990; 12 Suppl. 3: S349–63PubMedCrossRef
60.
Galgiani JN, Stevens DA, Graybill JR, et al. Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400-and 800-mg doses and observations at higher doses. Am J Med 1988; 84: 603–10
61.
Tucker RM, Denning DW, Arathoon EG, et al. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol 1990; 23: 593–601PubMedCrossRef
62.
Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. Ann Intern Med 2000; 133(9): 676–86PubMed
63.
Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis 2000; 30: 658–61PubMedCrossRef
64.
Tucker RM, Denning DW, Dupont B, et al. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990; 112: 108–12PubMed
65.
66.
Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev 1997; 10: 477–504PubMed
67.
Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–51PubMedCrossRef
68.
Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation — a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545–52PubMedCrossRef
69.
Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118: 495–503
70.
Kern W, Behre G, Rudolf T, et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998; 83: 291–301
71.
Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995; 172: 1035–41PubMedCrossRef
72.
Pfaller MA, Lockhart SR, Pujol C, et al. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. J Clin Microbiol 1998; 36: 1518–29PubMed
73.
Hoppe JE, Klingebiel T, Niethammer D. Selection of Candida glabrata in pediatric bone marrow transplant recipients receiving fluconazole. PediatrHematol Oncol 1994; 11: 207–10
74.
Wingard JR, Merz WG, Rinaldi MG, et al. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847–9PubMedCrossRef
75.
Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients [review]. Clin Infect Dis 1995; 20: 115–25PubMedCrossRef
76.
Prentice AG, Bradford GR. Prophylaxis of fungal infections with itraconazole during remission-induction therapy. Mycoses 1989; 32 Suppl. 1: 96–102PubMed
77.
Vreugdenhil G, Van Dijke BJ, Donnelly JP, et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993; 11(5-6): 353–8PubMedCrossRef
78.
Glasmacher A, Molitor E, Hahn C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998; 12: 1338–43PubMedCrossRef
79.
Huijgens PC, Simoons-Smit AM, van Loenen AC, et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 1999; 52: 376–80PubMedCrossRef
80.
Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32 Suppl. 1: 103–8PubMed
81.
Glasmacher A, Hahn C, Leutner C, et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443–51PubMedCrossRef
82.
Prentice AG, Warnock DW, Johnson SA, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994; 34: 247–52PubMedCrossRef
83.
Prentice AG, Warnock DW, Johnson SA, et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 1995; 36: 657–63PubMedCrossRef
84.
Reynes J, Bazin C, Ajana F, et al. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob Agents Chemother 1997; 41: 2554–8PubMed
85.
Michallet M, Persat F, Kranzhofer N, et al. Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation. Bone Marrow Transplant 1998; 21: 1239–43PubMedCrossRef
86.
Menichetti F, Favero AD, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 1999; 28: 250–5PubMedCrossRef
87.
Morgenstern GR, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 1999; 105: 901–11PubMedCrossRef
88.
Schafer-Korting M. Pharmacokinetic optimisation of oral antifungal therapy. Clin Pharmacokinet 1993; 25: 329–41PubMedCrossRef
89.
Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermatol 1999; 41: 237–49PubMedCrossRef
90.
MacKenzie-Wood AR, Whitfield MJ, Ray JE. Itraconazole and HIV protease inhibitors: an important interaction. Med J Aust 1999; 170: 46–7PubMed
91.
Brockmeyer NH, Tillmann I, Mertins L, et al. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur J Med Res 1997; 2: 377–83PubMed
92.
Trapnell CB, Klecker RW, Jamis-Dow C, et al. Glucuronidation of 3’-azido-3’-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob Agents Chemother 1998; 42: 1592–6PubMed
93.
Koks CH, van Heeswijk RP, Veldkamp AI, et al. Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir [letter]. AIDS 2000; 14: 89–90PubMedCrossRef
94.
EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668–72CrossRef
95.
Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23: 964–72PubMedCrossRef
96.
van’t Wout JW, Novakova I, Verhagen CA, et al. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991; 22: 45–52CrossRef
97.
Burch PA, Karp JE, Merz WG, et al. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987; 5: 1985–93PubMed
98.
Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147–202PubMedCrossRef
99.
Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997; 157: 1857–62PubMedCrossRef
100.
Lebeau B, Pelloux H, Pinel C, et al. Itraconazole in the treatment of aspergillosis: a study of 16 cases. Mycoses 1994; 37: 171–9PubMedCrossRef
101.
Popp AI, White MH, Quadri T, et al. Amphotericin B with and without itraconazole for invasive aspergillosis: a three-year retrospective study. Int J Infect Dis 1999; 3: 157–60PubMedCrossRef
102.
Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 1993; 36: 421–4PubMedCrossRef
103.
Boogaerts M, Garber G, Winston D, et al. Itraconazole (IT) compared with amphotericin B (AMB) as empirical therapy for persistent fever of unknown origin (FUO) in neutropenic patients (PTS). Bone Marrow Transplant 1999; 23 Suppl. 1: S111
104.
Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223–8PubMed
105.
Blum U, Windfuhr M, Buitrago-Tellez C, et al. Invasive pulmonary aspergillosis. MRI, CT, and plain radiographic findings and their contribution for early diagnosis. Chest 1994; 106: 1156–61
106.
Brenier-Pinchart MP, Pelloux H, Lebeau B, et al. Towards a molecular diagnosis of invasive aspergillosis? a review of the literature. J Mycol Med 1999; 9: 16–23
107.
Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139–47PubMed
108.
Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br JHaematol 1997; 98: 711–8CrossRef
109.
Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764–71PubMedCrossRef
110.
Rapp RP, Gubbins PO, Evans ME. Amphotericin B lipid complex. Ann Pharmacother 1997; 31: 1174–86PubMed
111.
Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–96PubMedCrossRef
112.
Ringden O, Jonsson V, Hansen M, et al. Severe and common side-effects of amphotericin B lipid complex (Abelcet). Bone Marrow Transplant 1998; 22: 733–4PubMedCrossRef
113.
Clark AD, McKendrick S, Tansey PJ, et al. Acomparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology, [erratum in Br J Haematol 1998; 103: 215] Br JHaematol 1998; 103: 198–204CrossRef
114.
White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296–302
115.
Boogaerts M, Tormans G, Maes E, et al. Cost-effectiveness analysis of Ambisome (AMB) vs amphotericin B (AMPHOB) in the empiric treatment of febrile neutropenia in adults and children. Blood 1996; 88 Suppl. 1: 501a
116.
Coukell AJ, Brogden RN. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 1998; 55: 585–612
117.
Verweij PE, Bos JJ, Severens JL, et al. Cost-effectiveness of liposomal amphotericin B for the treatment of invasive fungal infections in neutropenic patients [abstract no. O-14]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 25–27; San Diego, California, USA. Washington DC, USA: American Society for Microbiology, 1998: 609
118.
Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44: 1887–93PubMedCrossRef
119.
Vandewoude K, Vogelaers D, Decruyenaere J, et al. Concentrations in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob Agents Chemother 1997; 41: 2714–8PubMed
120.
Caillot D, Bassaris H, Seifert WF, et al. Efficacy, safety and pharmacokinetics of intravenous (IV) followed by oral itraconazole (ITR) in patients (pts) with invasive pulmonary aspergillosis (IPA) [abstract no. 1646]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, California, USA. Washington DC, USA: American Society for Microbiology, 1999: 575
121.
Annemans L, Moeremans K, Milligan DW, et al. Economic evaluation of intravenous itraconazole in presumed systemic fungal infections. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy [abstract no. 1867]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco, California, USA. Washington DC, USA: American Society for Microbiology, 1999: 743
Metadaten
Titel
Current Management of Fungal Infections
verfasst von
Jacques F. G. M. Meis
Paul E. Verweij
Publikationsdatum
01.12.2001
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe Sonderheft 1/2001
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200161001-00002

Weitere Artikel der Sonderheft 1/2001

Drugs 1/2001 Zur Ausgabe

Review Article

Clinical Experience with Itraconazole in Systemic Fungal Infections

Review Article

Pharmacology of Itraconazole

Review Article

An Overview of Fungal Infections

Review Article

The Cost of Treating Systemic Fungal Infections